• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Exploring the Use of NUDT5 Inhibitors to Treat Breast Cancer

by Bellbrook Labs / Monday, 23 August 2021 / Published in Emerging Targets, HTS Assays, Products
malignant adenocarcinoma could be treated by NUDT5 Inhibitors

NUDT5 is found to be overexpressed in certain cancers in humans

Could NUDT5 inhibitors lead to new cancer treatments? NUDIX hydrolases are a superfamily of enzymes are found in all classes of organisms and are responsible for hydrolyzing modified nucleoside diphosphates. One of the most well-studied NUDIX hydrolases is NUDT1 (also known as MTH1); it has been found to be associated with several diseases such as Parkinson’s disease and cancers1. However, another member of the superfamily, NUDT5, has recently gathered some attention for its association with certain cancers in humans.  NUDT5 hydrolyses substrates such as 8-OH-dGDP, 8-OH-dADP, and ADP-ribose (ADPR)2.

A recent study reported that high levels MTH1 and NUDT5 were observed in non-small-cell-lung cancer (NSCLC) cell lines and tissues and that higher levels of both proteins in NSCLC patients were associated with tumor metastasis and poorer prognosis3. Another new study published in PLOS ONE showed that NUDT5 expression was upregulated in human breast cancer cell lines and breast tumor tissues. The researchers also made the startling discovery that breast cancer patients with high NUDT5 expression profiles had a drastically poorer outcome than those with a lower NUDT5 expression profile4.

NUDT5 promotes carcinogenesis of breast cancer cells

The function of NUDT5 in regulating cellular proliferation was apparent when suppressing NUDT5 expression in some breast cancer cell lines dramatically reduced growth, migration, and invasiveness of the cancer cells4. NUDT5 also increases the aggressiveness of breast cancer and function as a key regulator of several oncogenic pathways5. Additionally, because NUDT5 aids in the production of nuclear ATP (energy), NUDT5 is important in ATP-dependent cellular processes such as chromatin remodeling, proliferation, and transcriptional regulation induced by estrogen in breast cancers. Thus, NUDT5 seems to play a profound role in promoting the carcinogenesis of breast cancers. This prompted several researchers to explore the idea of utilizing NUDT5 inhibitors to specifically target and inhibit NUDT5 to impede the carcinogenesis of breast cancer cells.

NUDT5 inhibitors are new potential anti-cancer drugs

A group of researchers at the Karolinska Institutet of Sweden have recently identified several potent NUDT5 inhibitors which are able to optimally target the protein6. The NUDT5 inhibitors were stifling nuclear ATP production, estrogen signaling, and cell proliferation of breast cancer cells and thus, may potentially be a promising treatment option for breast cancers6. More studies are required to further validate the safety and efficacy of using NUDT5 inhibitors to treat breast cancers, especially breast cancer patients who have high NUDT5 expression profiles.

Learn more about using a Transcreener Assay to detect NUDT5 enzymatic activity.

Go to NUDT5 Assay Page

References

  1. McLennan, A. G. The Nudix hydrolase superfamily. Cell. Mol. Life Sci. 63, 123–143 (2006). https://link.springer.com/article/10.1007/s00018-005-5386-7
  2. Ito, R. et al. Cleavage of oxidized guanine nucleotide and ADP sugar by human NUDT5 protein. J Biochem 149, 731–738 (2011). https://academic.oup.com/jb/article-abstract/149/6/731/2182605
  3. Li, D.-N. et al. The high expression of MTH1 and NUDT5 promotes tumor metastasis and indicates a poor prognosis in patients with non-small-cell lung cancer. Biochim Biophys Acta Mol Cell Res 1868, 118895 (2021). https://www.sciencedirect.com/science/article/abs/pii/S0167488920302536
  4. Zhang, H. et al. The high expression of NUDT5 indicates poor prognosis of breast cancer by modulating AKT / Cyclin D signaling. PLOS ONE 16, e0245876 (2021). https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0245876
  5. Pickup, K. E. et al. Expression of Oncogenic Drivers in 3D Cell Culture Depends on Nuclear ATP Synthesis by NUDT5. Cancers 11, 1337 (2019). https://www.mdpi.com/2072-6694/11/9/1337
  6. Page, B. D. G. et al. Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. Nat Commun 9, 250 (2018). https://www.nature.com/articles/s41467-017-02293-7
Tagged under: NUDIX 5 Assay, NUDT5 Assay, Transcreener AMP/GMP Assay

What you can read next

DDX3 inhibitors antiviral therapeutics
Can DDX3 Inhibitors Lead to the Discovery of Antiviral Therapies?
The Major Applications of Kinase Activity Assays
Pink Stethascope DOT1L Breast Cancer Target 420 X 280
How a Methyltransferase Activity Assay Could Help Identify Novel Breast Cancer Treatments

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...
  • Scientist Studying ALKPK1

    The Role of ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP